ICU MEDICAL INC/DE financials

  1. Home
  2. Financials
  3. ICUI
ICUI CIK 0000883984

Source: EDGAR filings · Built 2026-06-02T03:17:22Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 89.76M 123.51M 81.34M -153.12M 198.39M 130.39M
EBITDA 243.57M 262.48M 251.60M 192.25M 212.94M 183.79M
Working Capital 691.69M 885.80M 739.43M 740.64M 829.03M 725.29M
Net Debt 1.04B 1.33B 1.45B 1.53B -507.14M -343.40M
Gross Margin 36.84% 34.62% 32.75% 30.60% 37.34% 36.31%
Operating Margin 1.92% 1.80% 1.01% -1.88% 9.36% 7.72%
Net Margin 0.03% -4.94% -1.31% -3.26% 7.84% 6.83%
Return on Equity (ROE) 0.03% -5.99% -1.40% -3.55% 6.38% 5.78%
Return on Assets (ROA) 0.02% -2.80% -0.68% -1.65% 5.48% 4.93%
Current Ratio 2.39× 2.59× 2.53× 2.50× 5.13× 4.71×
Debt-to-Equity 0.63× 0.84× 0.80× 0.83× 0.03× 0.04×
Effective Tax Rate 55.92% -78.28% 62.13% — — 10.90%
Cash Conversion Ratio 245.69× -1.73× -5.60× 0.84× 2.59× 2.56×
Accruals Ratio -0.04× -0.08× -0.04× -0.00× -0.09× -0.08×
SBC % of Revenue 2.50% 1.97% 1.80% 1.58% 2.08% 1.88%
CapEx Coverage 2.00× 2.53× 1.96× -0.68× 3.87× 2.41×
Free Cash Flow Per Share $3.60 $5.06 $3.38 $-6.42 $9.11 $6.04

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 4755.67× — — — 50.07× 53.36×
P/FCF 39.59× 30.64× 29.54× — 26.06× 35.52×
FCF Yield 2.53% 3.26% 3.39% — 3.84% 2.82%
EV / EBITDA 18.73× 19.58× 15.33× 27.59× 21.34× 22.71×
P/S 1.58× 1.60× 1.07× 1.66× 3.84× 3.55×
P/B 1.66× 1.94× 1.13× 1.81× 3.13× 3.01×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenues 2.23B 2.38B 2.26B 2.28B 1.32B 1.27B
Cost of Goods and Services Sold 1.41B 1.56B 1.52B 1.58B 824.82M 809.51M
Gross Profit 822.04M 824.78M 739.87M 697.76M 491.49M 461.50M
Research and Development Expense 87.50M 88.61M 85.34M 92.98M 47.50M 42.95M
Selling, General and Administrative Expense 625.21M 638.76M 606.69M 608.35M 302.58M 283.95M
Operating Expenses 779.21M 781.82M 717.05M 740.66M 368.25M 363.33M
Operating Income (Loss) 42.83M 42.96M 22.82M -42.90M 123.25M 98.16M
Income Tax Expense (Benefit) 2.44M 51.68M -48.64M -40.12M 20.05M 10.62M
Net Income (Loss) Attributable to Parent 732.00K -117.69M -29.66M -74.29M 103.14M 86.87M
Earnings Per Share, Basic $0.03 $-4.83 $-1.23 $-3.11 $4.86 $4.16
Weighted Average Number of Shares Outstanding, Basic 24.64M 24.39M 24.09M 23.87M 21.21M 20.91M
Earnings Per Share, Diluted $0.03 $-4.83 $-1.23 $-3.11 $4.74 $4.02
Weighted Average Number of Shares Outstanding, Diluted 24.90M 24.39M 24.09M 23.87M 21.78M 21.59M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value — — — 208.78M 552.83M 396.10M
Assets, Current 1.19B 1.44B 1.22B 1.24B 1.03B 920.78M
Assets 4.05B 4.20B 4.38B 4.52B 1.88B 1.76B
Liabilities, Current 498.86M 556.18M 481.84M 494.56M 200.78M 195.49M
Long-term Debt, Excluding Current Maturities 1.27B 1.53B 1.58B 1.62B 0 —
Stockholders' Equity Attributable to Parent 2.12B 1.97B 2.12B 2.09B 1.62B 1.50B
Common Stock, Shares, Outstanding 24.69M 24.52M 24.14M 23.99M 21.28M 21.06M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 179.85M 204.03M 166.20M -62.13M 267.54M 222.75M
Payments to Acquire Property, Plant, and Equipment 88.04M 79.37M 83.89M 90.31M 68.54M 92.00M
Net Cash Provided by (Used in) Investing Activities 122.23M -88.96M -87.95M -1.91B -90.69M -98.14M
Payments for Repurchase of Common Stock 8.77M 11.99M 9.35M 10.88M 8.34M 12.88M
Net Cash Provided by (Used in) Financing Activities -311.52M -55.80M -35.98M 1.64B -16.87M -40.00K

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (ICUI CIK 0000883984), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

REZI

Resideo Technologies, Inc.

ATRO

ASTRONICS CORPORATION

HLLY

HOLLEY INC.